New research in animals sheds light on how Ritalin, the stimulant drug prescribed to millions of children each year in the United States for attention deficit hyperactivity disorder (ADHD), sheds light on how the drug works. The molecule appears to boost both attention and enhance the speed of learning by increasing the activity of the chemical messenger dopamine, according to new research in Nature Neuroscience.
Rats given Ritalin were able to more quickly learn that a combination of signals–a flash of light and sound–meant they could get a sugar water reward. But if the rats were also given a drug to block one type of dopamine receptor, the effect was lost. Treated animals also focused more intently on the task at hand, engaging in less unrelated behavior. Another drug, designed to block a second type of dopamine receptor, blocked Ritalin’s ability to increase focus.
Researchers also found that drug-treated animals had enhanced neural plasticity, or changes in strength of the connections between nerve cells. The ability of our neural circuits to change strength in response to new information underlies our ability to learn.
“Since we now know that Ritalin improves behavior through two specific types of neurotransmitter receptors, the finding could help in the development of better targeted drugs, with fewer side effects, to increase focus and learning,” said Antonello Bonci, MD, principal investigator at the Ernest Gallo Clinic and Research Center and professor of neurology at UCSF, in a statement from the university. The Gallo Center is affiliated with the UCSF Department of Neurology.
While Ritalin is mostly prescribed for children with ADHD, it also boosts cognitive function in healthy people. A number of studies suggest that a growing number of healthy adults and teens are taking Ritalin and similar drugs to aid in studying or work performance.
The gene-edited pig heart given to a dying patient was infected with a pig virus
The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.
Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging
The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.
Yann LeCun has a bold new vision for the future of AI
One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.
The dark secret behind those cute AI-generated animal images
Google Brain has revealed its own image-making AI, called Imagen. But don't expect to see anything that isn't wholesome.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.